[Transcenta Group - B: Strategic Cooperation Agreement with Joincare Medical Holdings Limited and Its Two Subsidiaries to Explore the Tokenization of Real-World Assets for Potential Financing of Innovative Oncology Therapies] Transcenta Group - B announced that on September 21, 2025, the company, along with its wholly-owned subsidiary Transcenta Oncology Inc., Joincare Medical Holdings Limited, and its two subsidiaries, signed a non-legally binding strategic cooperation agreement. According to the agreement, the parties will explore the potential issuance of real-world asset tokens on the Ethereum blockchain to fund the preclinical and clinical development of one or more selected projects among six potential "first-in-class" and/or "best-in-class" innovative oncology therapies. If the token issuance is successful, the proceeds from future financing will be used to accelerate the clinical and preclinical development of multiple innovative oncology antibody projects.